Compare EEX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | REPL |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 781.3M |
| IPO Year | 2017 | 2018 |
| Metric | EEX | REPL |
|---|---|---|
| Price | $4.94 | $8.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.70 | ★ $12.00 |
| AVG Volume (30 Days) | 115.2K | ★ 1.2M |
| Earning Date | 10-31-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $437,500,000.00 | N/A |
| Revenue This Year | $16.88 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $241.38 | ★ N/A |
| Revenue Growth | ★ 11.18 | N/A |
| 52 Week Low | $3.22 | $2.68 |
| 52 Week High | $5.45 | $14.80 |
| Indicator | EEX | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 34.70 |
| Support Level | $4.42 | $7.87 |
| Resistance Level | $5.09 | $9.41 |
| Average True Range (ATR) | 0.22 | 0.48 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 65.88 | 7.50 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.